{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T15:54:10Z","timestamp":1790351650210,"version":"4.1.0"},"reference-count":15,"publisher":"BMJ","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Case Reports"],"accepted":{"date-parts":[[2017,2,19]]},"abstract":"<jats:p>Myeloma is a haematological malignancy which typically follows a relapsing-remitting course. While treatment can control the myeloma and improve quality of life for given periods of time, remissions generally become progressively shorter with subsequent relapses, and patients ultimately enter a final refractory phase. To help control symptoms and enhance quality of life, some patients use complementary therapies as an adjunct to their conventional therapy. Here, we describe a myeloma patient who started a daily dietary supplement of curcumin when approaching her third relapse. In the absence of further antimyeloma treatment, the patient plateaued and has remained stable for the last 5 years with good quality of life.<\/jats:p>","DOI":"10.1136\/bcr-2016-218148","type":"journal-article","created":{"date-parts":[[2017,4,16]],"date-time":"2017-04-16T18:50:15Z","timestamp":1492368615000},"page":"bcr2016218148","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":15,"title":["Long-term stabilisation of myeloma with curcumin"],"prefix":"10.1136","volume":"2017","author":[{"given":"Abbas","family":"Zaidi","sequence":"first","affiliation":[{"name":"Department of Haematology, Barts Health NHS Trust, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maggie","family":"Lai","sequence":"additional","affiliation":[{"name":"Myeloma UK, Edinburgh, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jamie","family":"Cavenagh","sequence":"additional","affiliation":[{"name":"Department of Haematology, Barts Health NHS Trust, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2017,4,16]]},"reference":[{"key":"2025082801220134000_2017.mar27_2.bcr2016218148.1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.f3863"},{"key":"2025082801220134000_2017.mar27_2.bcr2016218148.2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-10-116129"},{"key":"2025082801220134000_2017.mar27_2.bcr2016218148.3","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2013.313"},{"key":"2025082801220134000_2017.mar27_2.bcr2016218148.4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/ajco.12115","article-title":"Why do some cancer patients receiving chemotherapy choose to take complementary and alternative medicines and what are the risks?","volume":"10","author":"Smith","year":"2014","journal-title":"Asia Pac J Clin Oncol"},{"key":"2025082801220134000_2017.mar27_2.bcr2016218148.5","doi-asserted-by":"publisher","DOI":"10.1016\/j.biocel.2008.06.010"},{"key":"2025082801220134000_2017.mar27_2.bcr2016218148.6","doi-asserted-by":"publisher","DOI":"10.1208\/s12248-012-9432-8"},{"key":"2025082801220134000_2017.mar27_2.bcr2016218148.7","doi-asserted-by":"publisher","DOI":"10.1016\/j.tips.2008.11.002"},{"key":"2025082801220134000_2017.mar27_2.bcr2016218148.8","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-05-1320"},{"key":"2025082801220134000_2017.mar27_2.bcr2016218148.9","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.3892\/ol.2015.2946","article-title":"A preliminary study of the effect of curcumin on the expression of p53 protein in a human multiple myeloma cell line","volume":"9","author":"Li","year":"2015","journal-title":"Oncol Lett"},{"key":"2025082801220134000_2017.mar27_2.bcr2016218148.10","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-08-0905"},{"key":"2025082801220134000_2017.mar27_2.bcr2016218148.11","first-page":"1","article-title":"Curcumin enhances the cytotoxic and chemo-sensitising effects of lenalidomide in human multiple myeloma cells","volume":"3","author":"Wong","year":"2013","journal-title":"J Hematol Malig"},{"key":"2025082801220134000_2017.mar27_2.bcr2016218148.12","doi-asserted-by":"crossref","first-page":"60","DOI":"10.4161\/15384047.2014.986997","article-title":"Curcumin induces cell death of the main molecular myeloma subtype, particularly the poor prognosis subgroups","volume":"16","author":"Gomez-Bougie","year":"2015","journal-title":"Cancer Biol Ther"},{"key":"2025082801220134000_2017.mar27_2.bcr2016218148.13","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1182\/blood.V110.11.1177.1177","article-title":"Curcumin downregulates NF-B and related genes in patients with multiple myeloma: results of a phase I\/II study","volume":"110","author":"Vadhan-Raj","year":"2007","journal-title":"Blood"},{"key":"2025082801220134000_2017.mar27_2.bcr2016218148.14","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-08-2217"},{"key":"2025082801220134000_2017.mar27_2.bcr2016218148.15","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.23159"}],"container-title":["BMJ Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bcr-2016-218148","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T08:22:10Z","timestamp":1756369330000},"score":1,"resource":{"primary":{"URL":"https:\/\/casereports.bmj.com\/lookup\/doi\/10.1136\/bcr-2016-218148"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,4,16]]},"references-count":15,"alternative-id":["10.1136\/bcr-2016-218148"],"URL":"https:\/\/doi.org\/10.1136\/bcr-2016-218148","relation":{},"ISSN":["1757-790X"],"issn-type":[{"value":"1757-790X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,4,16]]}}}